HaiHe Biopharma
PrivateLast Round
Private Placement
Sep 26, 2025
Est. Valuation
$525.3M
Total Funding Raised
$363.8M
Company Overview
HaiHe Biopharma operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Private Placement round in September 2025.
HaiHe Biopharma is a biotechnology company that specializes in the discovery, development, and commercialization of innovative anti-tumor drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HaiHe Biopharma Comparables
Compare HaiHe Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Apollomics | 88% | |
| Avistone Pharmaceuticals | 86% | |
| HUTCHMED (China) Limited | 82% |
For institutional investors. Book with your work email.
HaiHe Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Sep 26, 2025 | ||||
| IPO | May 28, 2024 | ||||
| Series C | Jun 1, 2023 | ||||
| IPO | Sep 22, 2021 | ||||
| Strategic | Aug 10, 2021 | ||||
Series B | Jul 27, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
HaiHe Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Guotai Junan Securities (Hong Kong) Limited | IPO |
| BioTrack Capital | Series A, Series B |
| Boyuan Capital | Series A |
| CCIC Capital | Series B |
| Jiangsu Ruihua Investment Holding Group Co., Ltd. | Series B |
| Hillhouse Investment | Series A |
| 招银国际金融有限公司 | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 28, 2024
$403M raised in IPO round.
- Sep 22, 2021
IPO round led by Guotai Junan Securities (Hong Kong) Limited.
For institutional investors. Book with your work email.
HaiHe Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HaiHe Biopharma's valuation, stock price, and market status.
Is HaiHe Biopharma a public or private company?
HaiHe Biopharma is a private company.
What is the current stock price of HaiHe Biopharma?
HaiHe Biopharma is a private company, so its shares have no public market price. Caplight tracks HaiHe Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HaiHe Biopharma worth (valuation)?
HaiHe Biopharma's valuation is estimated at $525.3M based on funding round data.
Can I buy HaiHe Biopharma stock?
HaiHe Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HaiHe Biopharma's last funding round?
HaiHe Biopharma's most recent funding round was Private Placement on September 26, 2025.
Who are the main investors in HaiHe Biopharma?
Key investors in HaiHe Biopharma include Guotai Junan Securities (Hong Kong) Limited, Deluxe Family Co., Ltd., Huagai Capital, Warburg Pincus.
Will HaiHe Biopharma IPO soon?
No public IPO plans have been announced for HaiHe Biopharma.
How can I track HaiHe Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in HaiHe Biopharma's shares on secondary markets.